Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
Peter W Hellings, Anju T Peters, Adam M Chaker, Enrico Heffler, Haixin Zhang, Amy Praestgaard, Scott Nash, Asif H Khan, Shahid Siddiqui, Juby A Jacob-Nara, Paul J Rowe, Yamo Deniz, Peter W Hellings, Anju T Peters, Adam M Chaker, Enrico Heffler, Haixin Zhang, Amy Praestgaard, Scott Nash, Asif H Khan, Shahid Siddiqui, Juby A Jacob-Nara, Paul J Rowe, Yamo Deniz
No abstract availableKeywords: medical therapy of chronic rhinosinusitis; olfaction; quality of life.
Conflict of interest statement
Peter W. Hellings: Regeneron Pharmaceuticals, Inc., Sanofi – advisory board member. Anju T. Peters: Regeneron Pharmaceuticals, Inc., Sanofi – advisory board member; AstraZeneca – research support and advisory board member; Optinose – consultant and research support. Adam M. Chaker: Technical University Munich (TUM) – research/clinical study grants: ALK Abello, Allergopharma, ASIT Biotech, AstraZeneca, Bencard/Allergen Therapeutics, European Institute of Technology (EIT), GlaxoSmithKline, LETI, Roche; ALK Abello, AstraZeneca, Bencart/Allergen Therapeutics, GlaxoSmithKline, Immunotek, LETI, Lofarma, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi‐Genzyme, Zeller advisory board member and/or speaker – all via TUM. Enrico Heffler: AstraZeneca, GlaxoSmithKline, Novartis, Sanofi – advisory board member. Yamo Deniz, Scott Nash, Shahid Siddiqui, and Haixin Zhang: Regeneron Pharmaceuticals, Inc. – employees, may hold stock and/or stock options in the company. Asif H. Khan, Juby A. Jacob‐Nara, Amy Praestgaard, and Paul J. Rowe: Sanofi – employees, may hold stock and/or stock options in the company.
Figures
References
- Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross‐sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57:32–42.
- Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy. 2021;14:127–134.
- Khan A, Huynh TMT, Vandeplas G, et al. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health‐related quality of life. Rhinology. 2019;57:343–351.
- Bhattacharyya N, Villeneuve S, Joish VN, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019;129:1969–1975.
- Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet. 2019;394:1638–1650.
- Chuang CC, Guillemin I, Bachert C, et al. Dupilumab in CRSwNP: responder analysis using clinically meaningful efficacy outcome thresholds. Laryngoscope. Published online November 24, 2021. 10.1002/lary.29911.
- Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147:29–36.
- Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1–464.
Source: PubMed